Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 74Gastrointestinal 22Breast 21Thoracic 19Head & Neck 19Genitourinary 18Dermatologic 8Lymphoid 5Sarcoma 4CNS 4Plasma cell 2Other hematologic neoplasm 2Other solid neoplasm 1Other 1Myeloid 1Endocrine 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 153Precursor Cell Lymphoblastic Leukemia-Lymphoma 92Hematologic Neoplasms 83Leukemia, Lymphocytic, Chronic, B-Cell 77Myelodysplastic Syndromes 53Leukemia 46Multiple Myeloma 40Lymphoma, Non-Hodgkin 33Lymphoma 33Leukemia, Myelogenous, Chronic, BCR-ABL Positive 25Burkitt Lymphoma 23Recurrence 20Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 20Leukemia, Biphenotypic, Acute 20Leukemia, Myelomonocytic, Chronic 19Lymphoma, Large B-Cell, Diffuse 18Neoplasms 17Myeloproliferative Disorders 17Lymphoma, Mantle-Cell 16Hodgkin Disease 15Lymphoma, Follicular 12Leukemia, B-Cell 12Lymphoma, B-Cell 11Waldenstrom Macroglobulinemia 10Leukemia, Hairy Cell 10Myelodysplastic-Myeloproliferative Diseases 9Anemia, Refractory, with Excess of Blasts 9Melanoma 8Lymphoma, B-Cell, Marginal Zone 8Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 6

Interventions

ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1erdafitinib 1defactinib 1dabrafenib 1copanlisib 1capivasertib 1binimetinib 1adavosertib 1X-Rays 1Trastuzumab 1Surveys and Questionnaires 1Sunitinib 1Specimen Handling 1PF-05280014 1Ontruzant 1Ogivri 1Nuclear Medicine Department, Hospital 1Nivolumab 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × Other hematologic neoplasm × 30 days × Clear all
NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT05108298 2026-05-07

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

Eastern Cooperative Oncology Group

Phase NA Recruiting
400 enrolled
BreastCNSDermatologicGastrointestinalGynecologicHead & NeckLymphoidOther hematologic neoplasmSarcoma

Bone Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Leukemia, Lymphoma, Melanoma, Sarcoma, Thyroid Neoplasms, Central Nervous System Neoplasms, Pyloric Stenosis, Hypertrophic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡